BIBF 1120 in Combination With Pemetrexed in Advanced Non Small Cell Lung Cancer (NSCLC)

NCT00979576 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

19

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG: BIBF 1120 M + Pemetrexed
DRUG: BIBF 1120 H + Pemetrexed
DRUG: BIBF 1120 RD + Pemetrexed
DRUG: BIBF 1120 L + Pemetrexed
DRUG: BIBF 1120 Placebo + Pemetrexed

Sponsor

Boehringer Ingelheim